ArticleJournal of oral biology and craniofacial research
Tomatidine suppresses PI3K/Akt signaling to induce apoptosis in oral squamous cell carcinoma: An in vitro and molecular docking study.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) has high mortality. Over the decades, there has been not substantial improvement in overall survival which is mostly attributed to lack of effective anticancer agent. Tomatidine, a steroidal alkaloid derived and sourced from unripe green tomatoes, has shown immense anticancer potential. However, its activity in OSCC remains largely uncharacterized. This research aims to evaluate the cytotoxic and pro-apoptotic effects of tomatidine in OSCC. Method: Target gene for Tomatidine on OSCC treatment was analyzed in the TCGA-HNSC dataset. Two gene were prioritized for network pharmacology to establish their relevance, followed by cheminformatics, drug-target screening, molecular docking, and ADME-T profiling to identify lead compounds. Gene expression and overall survival for target proteins (PI3K/AKT signaling) were examined using GEPIA an cBioportal databases. Functional validation for tomatidine was performed using KB cells via cell viability assay to assess the anticancer effect. Results: Tomatidine treatment reduced the viability of KB cells in a dosage-dependent manner. The docking simulations showed good binding affinities of tomatidine to PI3K (-8.4 kcal/mol), AKT (-8.8), and PTEN (-10.1), suggesting that tomatidine has a potential ability to disrupt PI3K/Akt signaling and apoptosis. Conclusion: Tomatidine has potent anticancer effects against OSCC cells inhibiting the PI3K/Akt signaling pathway and promoting apoptosis. These findings highlight the tomatidine utility as a natural anticancer compound.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.